Evidence map›Paper›PMID 34873459›Full record

ReviewAmerican journal of cancer research2021

From development to cancer - an ever-increasing role of AGR2.

Daria Jach, Yuzhu Cheng, Filip Prica, Laurent Dumartin, Tatjana Crnogorac-Jurcevic

Open access · greenAbstract readReview
In one paragraph

Review in American journal of cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. AGR2 activates the TGF-β/Smad signaling pathway to promote epithelial-mesenchymal transition, invasion, and metastasis in nasopharyngeal carcinoma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Frontiers in oncology · 2024
    Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Daria JachCentre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London London, UK.
Yuzhu ChengInstitute of Human Genetics, International Centre for Life, Newcastle University Newcastle Upon Tyne, UK.
Filip PricaMedical Clinic and Polyclinic I, Basic and Translational Research, Department of Cardiology Basic and Translational Research Munich, Germany.
Laurent DumartinAdvanced Accelerator Applications, Novartis Company Boulogne-Billancourt, France.
Tatjana Crnogorac-JurcevicCentre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London London, UK.
Queen Mary University of London · GBAdvanced Applications (United States) · USCentre for Life · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Anterior gradient 2, AGR2, is a small, 20 kDa protein that plays a vital role in oxidative protein folding in the endoplasmic reticulum. AGR2 is involved in several signal transduction pathways that are essential for cell survival. It was initially discovered in the African clawed frog,

Indexed as

AGR2anterior gradient 2cancerembryonic developmenttherapeutic targettumor biomarker

Identifiers

PMID34873459
PMCPMC8640830
OpenAlexW4287461718

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.